肝脏疾病是一种由病毒或有毒物连续侵害造成肝脏晚期纤维化的慢性疾病。目前，我们的治疗方法很有限，寻找治疗方法的大多数临床试验都失败了，部分原因是由于缺乏预测肝脏疾病发展的生物标志物。公司需要寻找一种新的生物标志物，对提高疾病的可控性会有很大的帮助，定期监测生物标志物也可以促进临床试验治疗药物的进一步发展。 具体可以查看https://www.innocentive.com/ar/challenge/9933671 Challenge Overview Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive license to practice their solutions for review, analysis and testing of the Proposed Solutions, an option for the grant of a further non-exclusive license, and an exclusive option to negotiate in good faith the terms of an exclusive license.
互联网增值电信业务许可证编号：渝B2-20120028 | 渝ICP备10200070号 互联网药品信息服务资格证：(渝)-经营性-2016-0011 渝公网备：50010801500236
康洲大数据 版权所有 Copyright © 2009-2021 药智网YAOZH.COM All Rights Reserved. 法律顾问：上海锦天城（重庆）律师事务所 程建律师
客户服务热线：400-678-0778 E-mail：firstname.lastname@example.org 商务合作QQ：845146016